Skip to content

uniQure QURE Return on equity

Return on equity at other companies

Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-325.6%+36.9pp
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
-49.6%+34.2pp
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-31.2%+43.7pp
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
19.9%+6.0pp
ALN
Alnylam PharmaceuticalsALNY
66.9%
Beam Therapeutics logo
Beam TherapeuticsBEAM
-47.1%

Other financials

Income statement

See full
Revenue$3.6M+127%
Gross profit$3.3M+144%
Operating income-$45.7M-16.2%
Net income-$53.5M-22.7%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$140.0M-35.6%
Total debt$63.3M-4.3%
Total equity$149.3M+343%
Total assets$778.7M+28.6%

Cash flow

See full
Operating cash flow-$38.2M+13.3%
CapEx$140.0K+11.1%
Free cash flow-$38.4M+13.2%

Valuation

See full
Market cap$3.09B+78.4%
Enterprise value$3.02B+124%
P/S170.9×+85.1×

Profitability

See full
Gross margin90.6%-2.9pp
Operating margin-1,059.7%+380pp
Net margin-1,154.4%+89.3pp
FCF margin-953.7%+169pp

Returns & leverage

See full
Debt / equity0.4×-1.5×
Current ratio10.4×-1.6×

Where this comes from

Calculated from uniQure’s reported figures.

Based on trailing twelve months.

The official record: uniQure’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about uniQure's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is uniQure's return on equity?
uniQure (QURE) reported return on equity of -228.2% in Q1 2026.
How has uniQure's return on equity changed year-over-year?
uniQure's return on equity increased by 5.4% year-over-year, from -241.2% to -228.2%.
What is the long-term trend for uniQure's return on equity?
Over 3 years (2020 to 2023), uniQure's return on equity has grown at a 27.0% compound annual growth rate (CAGR), from -44.1% to -90.2%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.